Design, synthesis, and SAR analysis of novel selective σ1 ligands

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 2, 2007, Pages 771-783

  Collina, Simona ^a   Loddo, Guya ^a   Urbano, Mariangela ^a   Linati, Laura ^a   Callegari, Athos ^a   Ortuso, Francesco ^b   Alcaro, Stefano ^b   Laggner, Christian ^c   Langer, Thierry ^c   Prezzavento, Orazio ^d   Ronsisvalle, Giuseppe ^d   Azzolina, Ornella ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Arylalkylamines; Molecular modeling; SAR studies; Sigma receptors

Indexed keywords

ARALKYLAMINE; N BENZYL N METHYL 3 (BIPHEN 4 YL)BUT 2 EN 1 YL AMINE; N BENZYL N METHYL 3 (BIPHEN 4 YL)BUTAN 1 AMINE; N BENZYL N METHYL 3 (NAPHTHALEN 2 YL)BUT 2 EN 1 YL AMINE; N BENZYL N METHYL 3 (NAPHTHALEN 2 YL)BUTAN 1 AMINE; N,N DIMETHYL 3 (6 HYDROXYNAPHTHALEN 2 YL)BUT 2 EN 1 YL AMINE; N,N DIMETHYL 3 (6 METHOXY NAPHTHALEN 2 YL)BUTAN 1 AMINE; N,N DIMETHYL 3 (6 METHOXYNAPHTHALEN 2 YL)BUT 2 EN 1 YL AMINE; N,N DIMETHYL 3 (6 METHOXYNAPHTHALEN 2 YL)BUTAN 1 AMINE; N,N DIMETHYL 3 (BIPHEN 4 YL)BUT 2 EN 1 YL AMINE; N,N DIMETHYL 3 (BIPHEN 4 YL)BUTAN 1 AMINE; N,N DIMETHYL 3 (NAPHTHALEN 1 YL)BUT 2 EN 1 YL AMINE; N,N DIMETHYL 3 (NAPHTHALEN 1 YL)BUTAN 1 AMINE; N,N DIMETHYL 3 (NAPHTHALEN 2 YL)BUT 2 EN 1 YL AMINE; N,N DIMETHYL 3 (NAPHTHALEN 2 YL)BUTAN 1 AMINE; SIGMA 1 OPIATE RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG SYNTHESIS; GUINEA PIG; MOLECULAR MODEL; NEUROPROTECTION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BRAIN; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, THIN LAYER; DRUG DESIGN; GUINEA PIGS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RADIOLIGAND ASSAY; RECEPTORS, SIGMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845315110     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.10.048     Document Type: Article

References (36)

1. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
2. Skuza G. Polish J. Pharmacol. 55 (2003) 923-934
3. Quirion R., Chicheportiche R., Contreras P.C., Johnson K.M., Lodge D., Tam S.W., Woods J.H., and Zukin S.R. Trends Pharmacol. Sci. 10 (1987) 444-446
4. Walker J.M., Bowen W.D., Walker F.O., Matsumoto R.R., de Costa B., and Rice K.C. Pharmacol. Rev. 42 (1990) 335-402
5. Quirion R., Bowen W.D., Itzhak Y., Junien J.L., Musacchio J.M., Rothman R.B., Su T.P., Tam S.W., and Taylor D.P. Trends Pharmacol. Sci. 13 (1992) 85-86
6. Hellewell S.B., Bruce A., Feinstein G., Orringer J., Williams W., and Bowen W.D. Eur. J. Pharmacol. 268 (1994) 9-18
7. Vilner B.J., John C.S., and Bowen W.D. Cancer Res. 55 (1995) 408-413
8. Itzhak Y. Sigma Receptors (1994), Academic Press, San Diego, CA
9. Hayashi T., and Su T.P. CNS Drugs 18 (2004) 269-284
10. Hanner M., Moebius F.F., Flandorfer A., Knaus H.G., Striessnig J., Kempner E., and Glossmann H. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8072-8077
11. Teruo H., and Tsung-Ping S. CNS Drugs 18 (2004) 269-284
12. Moebius F.F., Striessnig J., and Glossmann H. Trends Pharmacol. Sci. 18 (1997) 67-70
13. Bowen W.D. Pharm. Acta. Helv. 74 (2000) 211-218
14. Maurice T. Drug News Perspect. 15 (2002) 617-625
15. Tam S.W., and Cook L. Neurobiology 81 (1984) 5618-5621
16. Chien C.C., and Pasternak G.W. J. Pharmacol. Exp. Ther. 271 (1994) 1583-1590
17. Mei J., and Pasternak G.W. J. Pharmacol. Exp. Ther. 300 (2002) 1070-1074
18. Glennon R.A., Ablordeppey S.Y., Ismaiel A.M., El-Ashmawy M.B., Fischer J.B., and Howie K.B. J. Med. Chem. 37 (1994) 1214-1219
19. Gund T.M., Floyd J., and Jung D. J. Mol. Graphics Modell. 22 (2004) 221-230
20. Azzolina O., Collina S., Brusotti G., Rossi D., Callegari A., Linati L., Barbieri A., and Ghislandi V. Tetrahedron: Asymmetry 13 (2002) 1073-1081
21. Lipinski C.A., Lombardo F., Dominy B.W., and Freeney P.J. Adv. Drug Delivery Rev. 23 (1997) 3-25
22. Leo A.J., and Hoekman D. Perspect. Drug Discovery Des. 18 (2000) 19-38
23. Azzolina, O.; Collina, S.; Rossi, D.; Alcaro, S.; Ghislandi, V. Experimental and computational approaches to estimate the hydrophobicity of antinociceptive agents, First Magna Grecia Medicinal Chemistry Workshop on New Perspectives in Drug Research, Copanello, Catanzaro, Italy, 10-13 June 2001.
24. Banik B.K., Barakat K.J., Wagle D.R., Manhas M.S., and Bose A.K. J. Org. Chem. 64 (1999) 5746-5753
25. Farrugia L.J. J. Appl. Crystallogr. 30 (1997) 565
26. Catalyst 4.9, Accelrys Inc., San Diego, CA, http://www.accelrys.com, 2003.
27. Laggner C., Schieferer C., Fiechtner B., Poles G., Hoffmann R.D., Glossmann H., Langer T., and Moebius F.F. J. Med. Chem. 18 (2005) 4754-4764
28. Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., and Still W.C. J. Comput. Chem. 11 (1990) 440-467
29. Still W.C., Tempczyk A., Hawley R.C., and Hendrickson T. J. Am. Chem. Soc. 112 (1990) 6127-6129
30. Collina S., Loddo G., Barbieri A., Linati L., Alcaro S., Chimenti P., and Azzolina O. Tetrahedron: Asymmetry 15 (2004) 3601-3608
31. Chang G., Guida W.C., and Still W.C. J. Am. Chem. Soc. 111 (1989) 4379-4386
32. WebLab Viewer Lite 3.5; Accelrys (Molecular Simulations Inc.): San Diego, CA, 1999.
33. Matsumoto R.R., Bowen W.D., Tom M.A., Vo V.N., Truong D.D., and De Costa B.R. Eur. J. Pharmacol. 280 (1995) 301-310
34. DeHaven-Hudkins D.L., and Ford-Rice Y. Eur. J. Pharmacol. 227 (1992) 371-378
35. Macth R.H., Smith C.R., and Childers S.R. Life Sci. 57 (1995) 57-62
36. McPherson G.A. J. Pharmacol. Methods 14 (1985) 213-228